[Ga-68]-PNT6555 + [Lu-177]-PNT6555
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma
Trial Timeline
Jul 13, 2022 → Oct 2, 2024
NCT ID
NCT05432193About [Ga-68]-PNT6555 + [Lu-177]-PNT6555
[Ga-68]-PNT6555 + [Lu-177]-PNT6555 is a phase 1 stage product being developed by Eli Lilly for Pancreatic Ductal Adenocarcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05432193. Target conditions include Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Ductal Adenocarcinoma were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05432193 | Phase 1 | Terminated |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma